NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

4841.50 -27.00 (-0.55%)

92,359 NSE+BSE Volume

High vol. this week

NSE 05 Jun, 2025 1:58 PM (IST)

57,887.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Block Deal

Equity stake of 1.4% in Alkem Labs worth Rs 825 crore reportedly changes hands in a block deal See details

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

30 May 2019

4841.50

-0.55%

Alkem Labs-4QFY19 Result Update

Buy: Alkem Laboratories Ltd.

Target

Reliance Securities

Alkem Laboratories Ltd. average weekly volume is high.

Alkem Laboratories Ltd.

30 May 2019

4841.50

-0.55%

Favorable base effect comes into play; superior execution to drive profitability

Buy: Alkem Laboratories Ltd.

Target

Motilal Oswal

period due to changes in the distribution policy, adjusting for which domestic sales growth was in early teens. US business sales were up 19% YoY at INR4.8b. Other international business sales grew 20% YoY to INR1.2b. Margins supported by lower operating cost: Gross margin shrank 300bp YoY to 58.2% on account of product mix change (competition intensified for high-margin products). However, the EBITDA margin expanded 400bp YoY to 12.8% due to lower other expenses (-580bp YoY)/employee cost (-120bp YoY). EBITDA was up 81% YoY at INR2.3b due to high revenue growth and...

Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.

Alkem Laboratories Ltd.

26 Apr 2019

4841.50

-0.55%

ALKEM LABORATORIES LTD

Buy: Alkem Laboratories Ltd.

Ventura

We initiate with a BUY for a price target of Rs. 2,306 representing an

Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.

Alkem Laboratories Ltd.

26 Mar 2019

4841.50

-0.55%

FY19 an aberration, but outlook remains promising

Buy: Alkem Laboratories Ltd.

Target

Motilal Oswal

26 March 2019 ALKEM has ramped up its US sales to 6x over FY13-18 on new launches, reasonable market share gains in existing products, and partly on low base. For 9MFY19, ALKEM delivered strong 34% YoY growth to ~USD200m. We expect growth in ALKEMs US business to remain intact despite competition in one of its key products; newer approvals should offset the decline in base business and aid growth in the US generics segment. We expect the base effect to smoothen out and ALKEM to be back on track with aggressive growth in its chronic portfolio and on major therapies in the acute category, thereby aiding 14% revenue CAGR over FY19-21E. Based on 23% earnings CAGR expected over FY19-21E and led by healthy performance in the DF segment, enhanced margins in the US generics business, and attractive on the stock. For 9MFY19, US sales stood at USD200m and saw 34% YoY growth.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

11 Feb 2019

4841.50

-0.55%

Alkem Labs-3QFY19 Result Update

Alkem Laboratories Ltd.

Reliance Securities

Alkem Laboratories Ltd. average weekly volume is high.

Alkem Laboratories Ltd.

09 Feb 2019

4841.50

-0.55%

Alkem Labs (3QFY19): Good business at a reasonable price. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a revised TP of Rs 2,340 (22x Dec-20E EPS). Alkems 3QFY19 performance was in line with our expectations. A softer acute season led to a 1% fall in the domestic business, while the 44% jump in the US helped in maintaining 10% plus YoY top line growth. Poor business mix (lower India sales) and increased raw material cost led to a ~680bps drop in gross margin. As a result, EBITDA margin shrunk 450bps YoY and EBITDA declined 13% to Rs 3.1bn. Reported PAT at Rs 2.1bn was up 14% YoY owing to higher taxes in 3QFY18

BOB Capital Markets Ltd. released a Sell report for Alkem Laboratories Ltd. with a price target of 4527.0 on 30 May, 2025.

Alkem Laboratories Ltd.

05 Nov 2018, 08:53AM

4841.50

-0.55%

Alkem Labs (2QFY19): US drives growth. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 2,415 (22x Sep'20E EPS). Alkems 2QFY19 performance was ahead of expectation with EBITDA margin improving 614bps QoQ to 19% (100bps beat) and PAT coming in at Rs 2.6bn, down 19%YoY (16% beat). Revenues grew 3%YoY to Rs 19bn, in line with our estimates. Within segments, India business declined 6%YoY on a high base due to post-GST restocking last year, while US revenues grew 55%YoY to Rs 4.7bn, on the back of new product launches and currency tailwinds.

Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.

Alkem Laboratories Ltd.

03 Nov 2018, 03:19PM

4841.50

-0.55%

Alkem Laboratories Ltd Q2FY19 results Comment

Results Update: Alkem Laboratories Ltd.

HDFC Securities

Alkem Laboratories Ltd Q2FY19 results Comment Revenue rose by 14.94% to Rs. 1918.92 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 3.22% when compared with Q2FY18.

Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.

Alkem Laboratories Ltd.

02 Nov 2018

4841.50

-0.55%

Strong show; outlook remains promising

Buy: Alkem Laboratories Ltd.

Motilal Oswal

2 November 2018 muted growth of 3%YoY to INR19.2b (v/s est. of INR17.5b) on back of 6% YoY decline in domestic formulation (DF, 69% of sales), which was off-set by strong 55% YoY growth in the US business (25% of sales). Gross margins declined by ~180bp YoY (flat QoQ) to ~60.2% due to increased share of relatively low margin US business. Increased other expenses and employee cost (up ~270bp and ~60bp, as percentage of sales) led to contraction of ~570bp YoY in EBITDA margin to 19% (our est. Sequentially, EBITDA margin has expanded ~610bp due to improved operating leverage. R&D; spend was INR1.1b, 5.5% of sales v/s 5.9% of sales in 1QFY19. PAT declined by ~21% YoY to INR2.

Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.

Alkem Laboratories Ltd.

14 Aug 2018

4841.50

-0.55%

Alkem Labs - 1QFY19 Result Update

Buy: Alkem Laboratories Ltd.

Target

Reliance Securities

ff US FDA: Alkem is yet to receive The US FDA clearance for St. Louis facility. However, it has already received EIR for Daman unit (inspected in Mar'18), while the US FDA inspected its Baddi plant between 6-10th Aug-18 with zero observations....

BOB Capital Markets Ltd. released a Sell report for Alkem Laboratories Ltd. with a price target of 4527.0 on 30 May, 2025.

Is Alkem Laboratories Ltd. worth buying?

138 Votes:

Buy 78.99%

Sell 14.49%

Hold 6.52%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf